135 related articles for article (PubMed ID: 36712580)
1. Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania.
Ambrose EE; Kidenya BR; Charles M; Ndunguru J; Jonathan A; Makani J; Minja IK; Ruggajo P; Balandya E
J Blood Med; 2023; 14():37-47. PubMed ID: 36712580
[TBL] [Abstract][Full Text] [Related]
2. Health Related Quality of Life among Children with Sickle Cell Anaemia in Northwestern Tanzania.
Mwazyunga Z; Ambrose EE; Kayange N; Bakalemwa R; Kidenya B; Smart LR; Hokororo A
Open J Blood Dis; 2022 Jun; 12(2):11-28. PubMed ID: 38031542
[TBL] [Abstract][Full Text] [Related]
3. Complications of sickle cell anaemia in children in Northwestern Tanzania.
Saidi H; Smart LR; Kamugisha E; Ambrose EE; Soka D; Peck RN; Makani J
Hematology; 2016 May; 21(4):248-256. PubMed ID: 26868490
[TBL] [Abstract][Full Text] [Related]
4. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
[TBL] [Abstract][Full Text] [Related]
6. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea for secondary stroke prevention in children with sickle cell anaemia: a systematic review of clinical evidence and outcomes.
Aderinto N; Olatunji G; Kokori E; Abdulbasit M
Ann Med Surg (Lond); 2024 Feb; 86(2):1042-1047. PubMed ID: 38333270
[TBL] [Abstract][Full Text] [Related]
9. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia.
Jeste ND; Sánchez LM; Urcuyo GS; Bergés ME; Luden JP; Stuber SE; Latham TS; Mena R; Nieves RM; Ware RE
JMIR Res Protoc; 2017 Jun; 6(6):e107. PubMed ID: 28576754
[TBL] [Abstract][Full Text] [Related]
10. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
[TBL] [Abstract][Full Text] [Related]
11. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence.
Smith WR; McClish DK; Lottenberg R; Sisler IY; Sop D; Johnson S; Villella A; Liles D; Yang E; Chen I
Br J Haematol; 2022 Jan; 196(1):193-203. PubMed ID: 34786695
[TBL] [Abstract][Full Text] [Related]
13. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
15. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy in UK children with sickle cell anaemia: A single-centre experience.
Phillips K; Healy L; Smith L; Keenan R
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988427
[TBL] [Abstract][Full Text] [Related]
17. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Wang WC; Dwan K
Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
[TBL] [Abstract][Full Text] [Related]
18. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
[TBL] [Abstract][Full Text] [Related]
20. The role of hydroxyurea in decreasing the occurrence of vasso-occulusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia.
Azmet FR; Al-Kasim F; Alashram WM; Siddique K
Saudi Med J; 2020 Jan; 41(1):46-52. PubMed ID: 31915794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
